

Supporting Information

Versatile Redox-Responsive Polyplexes for the Delivery of Plasmid DNA, Messenger RNA, and CRISPR-Cas9 Genome-Editing Machinery

Yuyuan Wang^{1,2}, Ben Ma^{2,3}, Amr A. Abdeen², Guojun Chen^{1,2}, Ruosen Xie^{1,2},
Krishanu Saha^{2,4*}, and Shaoqin Gong^{1,2,4,5*}

1. Department of Materials Science and Engineering, University of Wisconsin–
Madison, Madison, WI 53715, USA.

2. Wisconsin Institute for Discovery, Wisconsin–Madison, Madison, WI 53715, USA

3. The Second Department of Hepatobiliary Surgery, Chinese PLA General Hospital,
Beijing 100853, P.R. China

4. Department of Biomedical Engineering, University of Wisconsin–Madison,
Madison, WI 53715, USA.

5. Department of Chemistry, University of Wisconsin–Madison, Madison, WI 53715,
USA.

*: Corresponding authors. Email: ksaha@wisc.edu; shaoqingong@wisc.edu




Figure S1. Synthesis scheme for the PBAP polymers, p(BAC-TET-Im) and PEG-p(BAC-TET-Im)-PEG, used to form non-crosslinked PBAP polyplexes.




Figure S2. ¹H-NMR spectra of p(BAC-TET-AD/Im) (A), p(BAC-TET-Im/β-CD) (B), and PEG-p(BAC-TET-AD/Im)-PEG (C) used to form crosslinked polyplexes. *: solvent residual peak.




Figure S3. Confirmation of host-guest interactions between β -CD and AD present in the CLPBAP polymers by $^1\text{H-NMR}$.




Figure S4. Effects of DNA polyplex formulation on the mean fluorescence intensity (MFI) of non-crosslinked DNA polyplexes. Cells were treated with Lipo 2000, non-crosslinked polyplexes with three different PBAP:PEG-PBAP-PEG:DNA weight ratios, and a polyplex with a PBAP:PEG-PBAP-PEG:DNA weight ratio of 48:28:1 with NLS (N/P ratio of 0.25). NS: not significant; *: $p < 0.05$; ***: $p < 0.001$.




Figure S5. Effects of AD:β-CD molar ratios on the MFI of cells treated with crosslinked DNA polyplexes with different AD:β-CD molar ratios. HEK 293 cells were treated with Lipo2000, non-crosslinked PBAP polyplexes, and crosslinked CLPBAP polyplexes with different crosslinker molar ratios. The MFI was measured 48 h post treatment. NS: not significant; ****: $p < 0.0001$.




Figure S6. Optimization of PBAP-based polymers and mRNA weight ratios for mRNA transfection. HEK293 cells were treated with Lipo 2000, non-crosslinked polyplexes with three different PBAP:PEG–PBAP–PEG:mRNA weight ratios, and crosslinked polyplexes with three different CLPBAP:PEG–CLPBAP–PEG:mRNA weight ratios. In the crosslinked polyplexes, the AD:β-CD molar ratio was fixed at 4:3. NS: not significant; *: $p < 0.05$; **: $p < 0.01$.




Figure S7. MFI analysis of non-crosslinked and crosslinked mRNA polyplexes in (A) HEK 293 cells and (B) RAW 264.7 cells at various time points. The weight ratio of PBAP:PEG–PBAP–PEG:mRNA in the non-crosslinked polyplexes and the weight ratio of CLPBAP:PEG–CLPBAP–PEG:mRNA in the crosslinked polyplexes were both fixed at 48:24:1. NS: not significant, *: $p < 0.01$; **: $p < 0.01$; ***: $p < 0.001$.




Figure S8. (A) Intracellular trafficking of the non-crosslinked DNA polyplexes with and without NLS. **(B)** Intracellular trafficking of the non-crosslinked and crosslinked mRNA polyplexes. Scale bar: 10 μm .




Figure S9. Optimization of the Lipo 2000 dosage using DNA as the payload. *: $p < 0.01$; **: $p < 0.01$; $n = 3$.

Table S1. Molecular weights of the polymers used to form the non-crosslinked and crosslinked polyplexes measured by GPC.

Polymer	Number-Average Molecular Weight (M_n)	Polydispersity Index (PDI)
p(BAC-TET)	8.5 kDa	1.6
PEG- p(BAC-TET)-PEG	19.1 kDa	1.7
p(BAC-TET-Im/AD)	9.2 kDa	1.7
p(BAC-TET-Im/ β -CD)	12.3 kDa	1.9
PEG-p(BAC-TET-Im/AD)-PEG	19.5 kDa	2.1

Table S2. Size and zeta-potential of non-crosslinked PBAP and crosslinked CLPBAP polyplexes.

Polyplex	Payload	Size by DLS (nm)	Zeta potential (mV)
Non-crosslinked	DNA	136	8.6
	mRNA	150	2.0
	RNP	143	6.7
	S1mplex	151	3.5
Crosslinked	DNA	168	7.9
	mRNA	191	-1.5
	RNP	170	5.4
	S1mplex	179	4.5